Pliant Therapeutics Files Form S-3 on Mar 30 Pliant filed a Form S-3 on Mar 30, 2026; S-3 eligibility commonly requires $75M public float, creating optionality for ATMs, registered debt or secondary offerings.

Pliant Therapeutics Files Form S-3 on Mar 30: Pliant filed a Form S-3 on Mar 30, 2026; S-3 eligibility commonly requires $75M public float, creating optionality for ATMs, registered debt or secondary offerings. 👈 Read full analysis #PliantTherapeutics #FormS3 #IPO #FinanceNews #Investment

Bay Area biotech company slashes staff after losing $655 million in value Pliant Therapeutics, based in South San Francisco, is laying off 45% of its workers in an attempt to extend its runway as it waits for a halted trial's results.

Pliant Therapeutics is laying off 45% of its staff, about 75 employees, after halting a key fibrosis drug study due to safety concerns, the South San Francisco biotech announced in an SEC filing. #southsanfrancisco #sanfrancisco #plianttherapeutics #fibrosis #bayarea #layoffs #bayarealayoffs